201 related articles for article (PubMed ID: 21856155)
1. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.
Radi M; Brullo C; Crespan E; Tintori C; Musumeci F; Biava M; Schenone S; Dreassi E; Zamperini C; Maga G; Pagano D; Angelucci A; Bologna M; Botta M
Bioorg Med Chem Lett; 2011 Oct; 21(19):5928-33. PubMed ID: 21856155
[TBL] [Abstract][Full Text] [Related]
2. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
3. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
4. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Molinari A; Fallacara AL; Di Maria S; Zamperini C; Poggialini F; Musumeci F; Schenone S; Angelucci A; Colapietro A; Crespan E; Kissova M; Maga G; Botta M
Bioorg Med Chem Lett; 2018 Nov; 28(21):3454-3457. PubMed ID: 30262428
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.
Cai J; Sun M; Wu X; Chen J; Wang P; Zong X; Ji M
Eur J Med Chem; 2013 May; 63():702-12. PubMed ID: 23567960
[TBL] [Abstract][Full Text] [Related]
6. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
7. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
10. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
11. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
12. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Wang Y; Shakespeare WC; Huang WS; Sundaramoorthi R; Lentini S; Das S; Liu S; Banda G; Wen D; Zhu X; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Dalgarno D; Clackson T; Sawyer TK
Bioorg Med Chem Lett; 2008 Sep; 18(17):4907-12. PubMed ID: 18691885
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
[TBL] [Abstract][Full Text] [Related]
14. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
15. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect.
El-Deeb IM; Lee SH
Bioorg Med Chem; 2010 Jun; 18(11):3860-74. PubMed ID: 20471842
[TBL] [Abstract][Full Text] [Related]
18. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
19. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
20. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.
Boschelli DH; Wang D; Wang Y; Wu B; Honores EE; Barrios Sosa AC; Chaudhary I; Golas J; Lucas J; Boschelli F
Bioorg Med Chem Lett; 2010 May; 20(9):2924-7. PubMed ID: 20363128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
